<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091338</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000387802</org_study_id>
    <secondary_id>NCI-04-C-0235</secondary_id>
    <nct_id>NCT00091338</nct_id>
    <nct_alias>NCT00088322</nct_alias>
  </id_info>
  <brief_title>Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Study of Subcutaneous &quot;CYT 99 007&quot; (Interleukin-7) in Conjunction With Peptide Immunization in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells.&#xD;
      Vaccines made from peptides may make the body build an immune response to kill tumor cells.&#xD;
      Combining interleukin-7 with vaccine therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 when&#xD;
      given with vaccine therapy in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of interleukin-7 (IL-7) when administered with&#xD;
           melanoma peptide vaccine emulsified in Montanide ISA-51 in patients with metastatic&#xD;
           melanoma.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the biological effects of this regimen on T-cell function and phenotype at&#xD;
           various doses and at the optimal biological dose in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic and pharmacodynamic characteristics of IL-7 in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the antitumor effects of IL-7, in terms of a dose-escalation strategy, in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of interleukin-7 (IL-7).&#xD;
&#xD;
      Patients receive IL-7 subcutaneously (SC) on days 0, 3, 6, 9, 12, 15, 18, and 21. Patients&#xD;
      also receive melanoma peptide vaccine comprising gp100 antigen and MART-1 antigen emulsified&#xD;
      in Montanide ISA-51 SC on days 0, 7, 14, and 21 in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of IL-7 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. After the MTD is determined, an additional 13&#xD;
      patients are treated at that dose level.&#xD;
&#xD;
      Patients are followed at 1, 2, and 5 weeks, at 3 and 6 months, and then at 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-37 patients will be accrued for this study within 1-12.3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-7</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Disease progression during or after prior interleukin-2 (IL-2) OR ineligible to&#xD;
             receive high-dose IL-2* OR has disease burden for which IL-2 is not indicated* NOTE:&#xD;
             *If patient did not receive prior IL-2, must have progressed after prior standard&#xD;
             first-line therapy (e.g., metastasectomy for single lesions or dacarbazine)&#xD;
&#xD;
          -  HLA-A*0201-positive disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3*&#xD;
&#xD;
          -  Absolute lymphocyte count ≥ 200/mm^3*&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  No proliferative hematologic disease NOTE: *For 2 consecutive readings performed on 2&#xD;
             different days&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT/PTT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
               -  Positive hepatitis B serology indicative of prior immunization (i.e., positive&#xD;
                  for antibody against hepatitis B surface antigen AND negative for antibody&#xD;
                  against hepatitis B core antigen) allowed&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.4 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction &gt; 45% by MUGA for patients ≥ 50 years of age OR with a history of&#xD;
             cardiac disease&#xD;
&#xD;
          -  No resting blood pressure &gt; 140/90 mm Hg with standard antihypertensive therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO/VA and FEV_1 &gt; 50% of predicted on pulmonary function test for smokers OR for&#xD;
             patients with clinical evidence of compromised pulmonary function&#xD;
&#xD;
          -  No history of severe asthma&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No splenomegaly&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other medical or psychiatric disease that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior cytokines&#xD;
&#xD;
          -  No prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  No concurrent growth factors&#xD;
&#xD;
          -  No concurrent monoclonal antibodies&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent cytokines&#xD;
&#xD;
          -  No other concurrent biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior intensive myeloablative chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 2 weeks since prior systemic corticosteroids for more than 72 hours in&#xD;
             duration&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
&#xD;
          -  No concurrent chronic anticoagulation therapy (e.g., high-dose warfarin, heparin, or&#xD;
             aspirin)&#xD;
&#xD;
               -  Concurrent low-dose warfarin (1-2 mg) allowed&#xD;
&#xD;
          -  No concurrent chronic medication for asthma&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006 May-Jun;29(3):313-9.</citation>
    <PMID>16699374</PMID>
  </results_reference>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

